[go: up one dir, main page]

CY1123509T1 - Αλατα και στερεες μορφες ενος αντιβιοτικου μονοβακταμης - Google Patents

Αλατα και στερεες μορφες ενος αντιβιοτικου μονοβακταμης

Info

Publication number
CY1123509T1
CY1123509T1 CY20201100840T CY201100840T CY1123509T1 CY 1123509 T1 CY1123509 T1 CY 1123509T1 CY 20201100840 T CY20201100840 T CY 20201100840T CY 201100840 T CY201100840 T CY 201100840T CY 1123509 T1 CY1123509 T1 CY 1123509T1
Authority
CY
Cyprus
Prior art keywords
salts
solid forms
monobactam
antibiotic
oxo
Prior art date
Application number
CY20201100840T
Other languages
English (en)
Inventor
Eric Aubin
Andreas Fisch
Michael Mutz
Marc SCHOENHENTZ
Anthony Casarez
Zaixing LI
Mika Lindvall
Heinz Ernst Moser
Folkert Reck
Vijay SETHURAMAN
Robert Lowell Simmons
Bernd Ulrich Riebesehl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1123509T1 publication Critical patent/CY1123509T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Παρέχονται νέες στερεές μορφές, άλατα και πολύμορφα του 1-(((Ζ)-(1-(2-αμινοθειαζολ-4-υλο}-2-οξο-2-(((3S,4R)-2-οξο-4-((2-οξοοξαζολιδιν-3-υλο)μεθυλ)-1-σουλφοαζετιδιν-3-υλο)αμινο)αιθυλιδενο)αμινο)οξυ)-κυκλοπροπανοκαρβοξυλικού οξέος (αναφέρεται εδώ ως ένωση Χ), φαρμακευτικές συνθέσεις που τα περιέχουν, και διαδικασίες για την παρασκευή και χρήση τους στη θεραπεία.
CY20201100840T 2015-09-23 2020-09-07 Αλατα και στερεες μορφες ενος αντιβιοτικου μονοβακταμης CY1123509T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562222430P 2015-09-23 2015-09-23
PCT/CN2016/099482 WO2017050218A1 (en) 2015-09-23 2016-09-20 Salts and solid forms of monobactam antibiotic

Publications (1)

Publication Number Publication Date
CY1123509T1 true CY1123509T1 (el) 2022-03-24

Family

ID=58385723

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100840T CY1123509T1 (el) 2015-09-23 2020-09-07 Αλατα και στερεες μορφες ενος αντιβιοτικου μονοβακταμης

Country Status (27)

Country Link
US (1) US10919887B2 (el)
EP (1) EP3353175B1 (el)
JP (1) JP6837480B2 (el)
KR (1) KR102749337B1 (el)
CN (1) CN108137573B (el)
AU (1) AU2016327264B2 (el)
CA (1) CA2999794C (el)
CL (2) CL2018000745A1 (el)
CY (1) CY1123509T1 (el)
DK (1) DK3353175T3 (el)
EA (2) EA037569B1 (el)
ES (1) ES2817537T3 (el)
HK (1) HK1257271A1 (el)
HR (1) HRP20201423T1 (el)
HU (1) HUE050849T2 (el)
IL (1) IL258254B (el)
LT (1) LT3353175T (el)
MA (1) MA42946B1 (el)
MX (1) MX377532B (el)
PH (1) PH12018500653B1 (el)
PL (1) PL3353175T3 (el)
PT (1) PT3353175T (el)
RS (1) RS60805B1 (el)
RU (1) RU2754180C2 (el)
SI (1) SI3353175T1 (el)
SM (1) SMT202000480T1 (el)
WO (1) WO2017050218A1 (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3661933B1 (en) 2017-08-02 2022-03-23 Novartis AG Process for preparing 1-(((z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3s,4r)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3- yl)amino)ethylidene)amino)oxy)cyclopropane carboxylic acid
US11760866B2 (en) * 2017-08-16 2023-09-19 Lg Chem, Ltd. White pigment comprising ZIF-based powder, polymer resin film and method for changing color of medium using white pigment
WO2019092180A1 (en) * 2017-11-10 2019-05-16 Novartis Ag Administration of monobactam for the treatment of urinary tract infection
CN111511737B (zh) * 2018-01-29 2022-10-18 南京明德新药研发有限公司 用于治疗细菌感染的单环β-内酰胺化合物
JP7179185B2 (ja) * 2018-12-18 2022-11-28 メッドシャイン ディスカバリー インコーポレイテッド 医薬の製造おける単環式β－ラクタム化合物の使用
US20230037556A1 (en) * 2019-11-22 2023-02-09 Suzhou Erye Pharmaceutical Co., Ltd SULFONYLUREA RING SUBSTITUTED MONOCYCLIC beta-LACTAM ANTIBIOTICS
US20230022708A1 (en) 2019-12-19 2023-01-26 Medshine Discovery Inc. Application of compound in drug preparation
CN113754651B (zh) 2020-06-02 2023-04-18 中国医学科学院医药生物技术研究所 一种β-内酰胺化合物、其用途及其制备方法
WO2022027439A1 (en) * 2020-08-06 2022-02-10 Ningxia Academy Of Agriculture And Forestry Sciences β-LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS
WO2022185241A1 (en) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Process for manufacturing a monobactam antibiotic
WO2022185240A1 (en) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Formulation of a monobactam antibiotic
CN115304594B (zh) * 2022-10-12 2023-02-14 苏州二叶制药有限公司 磺酰脲环取代的化合物的盐型及其晶型

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ196202A (en) 1980-02-07 1984-07-31 Squibb & Sons Inc Beta-lactam antibiotics (of azetidine-sulphonic acid type)
US4775670A (en) 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
EP0048953B1 (en) 1980-09-29 1988-03-09 E.R. Squibb & Sons, Inc. Beta-lactam antibiotics
WO1982001873A1 (en) 1980-12-05 1982-06-10 Takeda Chemical Industries Ltd 1-sulfo-2-oxoazetidine derivatives and process for their preparation
US4782147A (en) 1980-12-05 1988-11-01 Takeda Chemical Industries, Ltd. 1-sulfo-2-oxoazetidine derivatives and their production
CA1262128A (en) 1981-08-27 1989-10-03 Christian N. Hubschwerlen .beta.-lactams
IL67451A (en) 1981-12-25 1987-10-20 Takeda Chemical Industries Ltd 4-cyano-2-azetidinones and production thereof and process for the preparation of 4-carbamoyl-2-azetidinones using them
AU564150B2 (en) * 1982-04-30 1987-08-06 Takeda Chemical Industries Ltd. 1-sulfo-2-azetidinone derivatives
HU189290B (en) 1982-05-31 1986-06-30 Banyu Pharmaceutical Co Ltd,Jp Process for preparing new 2-oxo-1-azetidine-sulphonic acid derivatives and pharmaceutically acceptable salts thereof, further pharmaceutical compositions containing such derivatives as active substances
DE3377061D1 (en) 1982-06-03 1988-07-21 Hoffmann La Roche Process for the preparation of 1-sulfo-2-oxoazetidine derivatives
JPS6153282A (ja) 1984-08-22 1986-03-17 Banyu Pharmaceut Co Ltd 単環β−ラクタム誘導体
JPS6153283A (ja) 1984-08-24 1986-03-17 Banyu Pharmaceut Co Ltd ２−オキソ−１−アゼチジンスルホン酸誘導体
US4610824A (en) 1984-10-09 1986-09-09 E. R. Squibb & Sons, Inc. Hydrazide derivatives of monocyclic beta-lactam antibiotics
US5112968A (en) 1989-07-28 1992-05-12 E. R. Squibb & Sons, Inc. Monobactam hydrazide derivatives
ES2602969T3 (es) 2008-10-31 2017-02-23 Shionogi & Co., Ltd. Cefalosporinas que tienen un grupo catecol
EP2379546A1 (en) 2008-12-19 2011-10-26 Pfizer Inc. Monocarbams
MX2013005994A (es) 2010-11-29 2013-07-15 Pfizer Monobactamas.
UY34585A (es) 2012-01-24 2013-09-02 Aicuris Gmbh & Co Kg Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
CN103044416A (zh) 2012-12-17 2013-04-17 浙江华方药业有限责任公司 一种卡芦莫南钠的合成方法
WO2015103583A1 (en) 2014-01-06 2015-07-09 President And Fellows Of Harvard College Monobactams and methods of their synthesis and use
UA121383C2 (uk) * 2014-03-24 2020-05-25 Новартіс Аг Органічні сполуки, що є монобактамами, для лікування бактеріальних інфекцій

Also Published As

Publication number Publication date
SMT202000480T1 (it) 2020-11-10
PL3353175T3 (pl) 2021-02-22
RU2018114480A3 (el) 2020-06-09
DK3353175T3 (da) 2020-09-14
CL2019003324A1 (es) 2020-04-17
ES2817537T3 (es) 2021-04-07
RU2018114480A (ru) 2019-10-23
JP6837480B2 (ja) 2021-03-03
EP3353175A4 (en) 2019-06-26
CN108137573B (zh) 2021-06-11
AU2016327264B2 (en) 2019-06-27
EA201890771A1 (ru) 2018-09-28
AU2016327264A1 (en) 2018-05-10
PH12018500653B1 (en) 2022-05-04
CN108137573A (zh) 2018-06-08
MA42946B1 (fr) 2020-10-28
RU2754180C2 (ru) 2021-08-30
PH12018500653A1 (en) 2018-10-01
RS60805B1 (sr) 2020-10-30
EP3353175B1 (en) 2020-08-12
MX2018003592A (es) 2018-06-18
MA42946A (fr) 2018-08-01
JP2018528241A (ja) 2018-09-27
KR102749337B1 (ko) 2025-01-03
PT3353175T (pt) 2020-09-10
US10919887B2 (en) 2021-02-16
WO2017050218A1 (en) 2017-03-30
CA2999794C (en) 2023-08-15
EA037569B1 (ru) 2021-04-15
CL2018000745A1 (es) 2018-06-22
IL258254B (en) 2021-02-28
HRP20201423T1 (hr) 2020-12-11
MX377532B (es) 2025-03-10
EA202092620A1 (ru) 2021-06-30
LT3353175T (lt) 2020-10-12
SI3353175T1 (sl) 2020-11-30
IL258254A (en) 2018-05-31
US20180273522A1 (en) 2018-09-27
EP3353175A1 (en) 2018-08-01
CA2999794A1 (en) 2017-03-30
HUE050849T2 (hu) 2021-01-28
HK1257271A1 (zh) 2019-10-18
BR112018005805A2 (pt) 2018-10-16
KR20180054816A (ko) 2018-05-24

Similar Documents

Publication Publication Date Title
CY1123509T1 (el) Αλατα και στερεες μορφες ενος αντιβιοτικου μονοβακταμης
CY1120703T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
BR112019003504A2 (pt) compostos de amino-pirrolopirimidinona e métodos de uso dos mesmos
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
BR112017010354B8 (pt) Compostos de triazolopirimidina, seu uso, e composição farmacêutica
BR112016008468A2 (pt) Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer
EA201892838A1 (ru) Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
CL2015001667A1 (es) Derivados de manosa para tratar infecciones bacterianas.
CY1118678T1 (el) Παραγωγα καρβοξαμιδιου χλωρο-πυραζινης χρησιμα για την θεραπευτικη αντιμετωπιση ασθενειων που ευνοουνται απο την ανεπαρκη ενυδατωση του βλεννογονου
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
MX376329B (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
CY1122313T1 (el) Ορβεπιταντη για την αγωγη του χρονιου κνησμου
BR112017009651A2 (pt) composto, composição farmacêutica, e, método para tratamento de uma infecção por protozoário intracelular, uma infecção viral ou um câncer.
EA201700504A1 (ru) 5-ароматическое алкинилзамещенное бензомидное соединение и способ его получения, фармацевтическая композиция и их применение
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
MX375068B (es) Un grupo de compuestos utilizados para el tratamiento o prevencion de hiperuricemia o gota.
TN2017000096A1 (en) 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as sgrm modulators.
BR112018006545A2 (pt) ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
JOP20190050A1 (ar) مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي
BR112017004796A2 (pt) método para utilizar derivados de ácido hidroxâmico e substância antibacterial em combinação